{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:18Z","timestamp":1792782798211,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Thuringian Ministry of Education, Science, and Culture","award":["Nanocellculture FKZ-B714-09064"],"award-info":[{"award-number":["Nanocellculture FKZ-B714-09064"]}],"id":[{"id":"https:\/\/ror.org\/00949d647","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Federal Ministry of Education and Research","award":["Center of Innovation Competence FKZ-03ZIK465"],"award-info":[{"award-number":["Center of Innovation Competence FKZ-03ZIK465"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Carl-Zeiss Foundation","award":["P2024-02-019"],"award-info":[{"award-number":["P2024-02-019"]}]},{"name":"German Research Foundation\/Deutsche Forschungsgemeinschaft","award":["KR2291"],"award-info":[{"award-number":["KR2291"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Walter Schulz Stiftung"},{"name":"Brigitte und Dr. Konstanze Wegener-Stiftung","award":["project 110"],"award-info":[{"award-number":["project 110"]}],"id":[{"id":"https:\/\/ror.org\/00bgszw56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","award":["DJCLS 09 R\/204"],"award-info":[{"award-number":["DJCLS 09 R\/204"]}],"id":[{"id":"https:\/\/ror.org\/00826gz80","id-type":"ROR","asserted-by":"crossref"}]},{"name":"H.W. & J. Hector Stiftung","award":["project M 2419"],"award-info":[{"award-number":["project M 2419"]}],"id":[{"id":"https:\/\/ror.org\/0427ycx88","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004426","name":"Dr. Werner Jackst\u00e4dt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma associated with an extremely poor prognosis. This study evaluates the therapeutic potential of targeted, non-DNA-damaging small-molecule inhibitors in an in vitro DSRCT model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We characterized the genomic architecture of the JN-DSRCT-1 cell line using fluorescence in situ hybridization (FISH) and sequencing of the tumor suppressor\n                      <jats:italic>TP53<\/jats:italic>\n                      . In silico analysis was performed to identify shared vulnerabilities between DSRCT and Ewing sarcoma (ES). Using flow cytometry (assessing cell death, mitochondrial membrane potential loss, caspase\u20133 activity, and cell cycle distribution) and quantitative real-time PCR (qPCR), we systematically evaluated a small-molecule screening panel. The panel targeted chromatin acetylation (entinostat, vorinostat, tenovin-1), p53 pathway activity (RETRA, nutlin-3, RITA), receptor tyrosine kinases (imatinib), and transcription factor DNA-binding dynamics (mithramycin).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      JN-DSRCT-1 cells exhibited complex aneuploidy, and we confirmed the presence of the pathognomonic balanced\n                      <jats:italic>EWSR1::WT1<\/jats:italic>\n                      translocation. Histone deacetylase inhibitors (entinostat, vorinostat) and nutlin-3 (an MDM2 antagonist) triggered robust intrinsic apoptosis and upregulated p53 target genes (p21, PUMA, and NOXA). Mithramycin demonstrated high cytotoxicity, whereas imatinib was ineffective. Pan-caspase inhibition using z-VAD-FMK rescued cells from entinostat-, vorinostat-, nutlin-3-, and mithramycin-induced death, but failed to protect against tenovin-1, RITA, or RETRA, indicating the activation of caspase-independent cell death pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DSRCT cells display high sensitivity to histone deacetylase inhibition, p53 pathway activation, and mithramycin. Among these, histone deacetylase inhibition alone or in combination with other small molecule drugs represents a particularly promising strategy for overcoming DSRCT cell survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06630-6","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:03:43Z","timestamp":1791014623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of novel targeted small-molecule therapeutics in desmoplastic small round cell tumor (DSRCT) cells"],"prefix":"10.1007","volume":"152","author":[{"given":"Anne","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Liehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Sonnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2240-8261","authenticated-orcid":false,"given":"Christian","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"6630_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67810-3","volume":"14","author":"RBV Abreu","year":"2024","unstructured":"Abreu RBV, Pereira AS, Rosa MN, Ashton-Prolla P, Silva VAO, Melendez ME, Palmero EI (2024) Functional evaluation of germline TP53 variants identified in Brazilian families at-risk for Li-Fraumeni syndrome. Sci Rep 14:17187. https:\/\/doi.org\/10.1038\/s41598-024-67810-3","journal-title":"Sci Rep"},{"key":"6630_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00518","volume":"10","author":"TS Bexelius","year":"2020","unstructured":"Bexelius TS, Wasti A, Chisholm JC (2020) Mini-review on targeted treatment of desmoplastic small round cell tumor. Front Oncol 10:518. https:\/\/doi.org\/10.3389\/fonc.2020.00518","journal-title":"Front Oncol"},{"key":"6630_CR3","doi-asserted-by":"publisher","first-page":"7460","DOI":"10.1038\/s41467-024-51851-3","volume":"15","author":"G Boulay","year":"2024","unstructured":"Boulay G, Broye LC, Dong R, Iyer S, Sanalkumar R, Xing YH, Buisson R, Rengarajan S, Naigles B, Duc B, Volorio A, Awad ME, Renella R, Chebib I, Nielsen GP, Choy E, Cote GM, Zou L, Letovanec I, Stamenkovic I, Rivera MN, Riggi N (2024) EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors. Nat Commun 15:7460. https:\/\/doi.org\/10.1038\/s41467-024-51851-3","journal-title":"Nat Commun"},{"key":"6630_CR4","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-12-2211","volume":"19","author":"M Burmakin","year":"2013","unstructured":"Burmakin M, Shi Y, Hedstrom E, Kogner P, Selivanova G (2013) Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 19:5092\u20135103. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2211","journal-title":"Clin Cancer Res"},{"key":"6630_CR5","doi-asserted-by":"publisher","first-page":"57011","DOI":"10.18632\/oncotarget.10935","volume":"7","author":"D Campa","year":"2016","unstructured":"Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, Neoptolemos JP, Niesen W, Vodicka P, Delle Fave G, Bueno-de-Mesquita HB, Gazouli M, Pacetti P, Di Leo M, Ito H, Kluter H, Soucek P, Corbo V, Yamao K, Hosono S, Kaaks R, Vashist Y, Gioffreda D, Strobel O, Shimizu Y, Dijk F, Andriulli A, Ivanauskas A, Bugert P, Tavano F, Vodickova L, Zambon CF, Lovecek M, Landi S, Key TJ, Boggi U, Pezzilli R, Jamroziak K, Mohelnikova-Duchonova B, Mambrini A, Bambi F, Busch O, Pazienza V, Valente R, Theodoropoulos GE, Hackert T, Capurso G, Cavestro GM, Pasquali C, Basso D, Sperti C, Matsuo K, Buchler M, Khaw KT, Izbicki J, Costello E, Katzke V, Michalski C, Stepien A, Rizzato C, Canzian F (2016) Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A\/2B region affect pancreatic cancer risk. Oncotarget 7:57011\u201357020. https:\/\/doi.org\/10.18632\/oncotarget.10935","journal-title":"Oncotarget"},{"key":"6630_CR6","first-page":"547","volume":"30","author":"J Chao","year":"2010","unstructured":"Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA (2010) Phase II clinical trial of imatinib mesylate in therapy of KIT and\/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res 30:547\u2013552","journal-title":"Anticancer Res"},{"key":"6630_CR7","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357\u20135364. https:\/\/doi.org\/10.1200\/JCO.2005.14.068","journal-title":"J Clin Oncol"},{"key":"6630_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/2159-8290.CD-13-1037","volume":"4","author":"BD Crompton","year":"2014","unstructured":"Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, Sunol M, McKenna A, Sivachenko A, Cibulskis K, Lawrence MS, Stojanov P, Rosenberg M, Ambrogio L, Auclair D, Seepo S, Blumenstiel B, DeFelice M, Imaz-Rosshandler I, Schwarz-Cruz YCA, Rivera MN, Rodriguez-Galindo C, Fleming MD, Golub TR, Getz G, Mora J, Stegmaier K (2014) The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 4:1326\u20131341. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-1037","journal-title":"Cancer Discov"},{"key":"6630_CR9","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.3390\/biomedicines11123343","volume":"11","author":"A Danishevich","year":"2023","unstructured":"Danishevich A, Bilyalov A, Nikolaev S, Khalikov N, Isaeva D, Levina Y, Makarova M, Nemtsova M, Chernevskiy D, Sagaydak O, Baranova E, Vorontsova M, Byakhova M, Semenova A, Galkin V, Khatkov I, Gadzhieva S, Bodunova N (2023) CDKN2A gene mutations: implications for hereditary cancer syndromes. Biomedicines 11:3343. https:\/\/doi.org\/10.3390\/biomedicines11123343","journal-title":"Biomedicines"},{"key":"6630_CR10","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jnci\/djab019","volume":"113","author":"C De Souza","year":"2021","unstructured":"De Souza C, Madden J, Koestler DC, Minn D, Montoya DJ, Minn K, Raetz AG, Zhu Z, Xiao WW, Tahmassebi N, Kathi HR, Nelson N, Karnezis AN, Chien J (2021) Effect of the p53 P72R polymorphism on mutant TP53 allele selection in human cancer. J Natl Cancer Inst 113:1246\u20131257. https:\/\/doi.org\/10.1093\/jnci\/djab019","journal-title":"J Natl Cancer Inst"},{"key":"6630_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162\u2013165. https:\/\/doi.org\/10.1038\/359162a0","journal-title":"Nature"},{"key":"6630_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/0008-5472.CAN-23-2573","volume":"84","author":"JK Dermawan","year":"2024","unstructured":"Dermawan JK, Slotkin E, Tap WD, Meyers P, Wexler L, Healey J, Vanoli F, Vanderbilt CM, Antonescu CR (2024) Chromoplexy is a frequent early clonal event in EWSR1-rearranged round cell sarcomas that can be detected using clinically validated targeted sequencing panels. Cancer Res 84:1504\u20131516. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2573","journal-title":"Cancer Res"},{"key":"6630_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s12276-025-01470-9","volume":"57","author":"SH Dho","year":"2025","unstructured":"Dho SH, Cho M, Woo W, Jeong S, Kim LK (2025) Caspases as master regulators of programmed cell death: apoptosis, pyroptosis and beyond. Exp Mol Med 57:1121\u20131132. https:\/\/doi.org\/10.1038\/s12276-025-01470-9","journal-title":"Exp Mol Med"},{"key":"6630_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferracin M (2023) ARID1A in cancer: friend or foe? Front Oncol 13:1136248. https:\/\/doi.org\/10.3389\/fonc.2023.1136248","journal-title":"Front Oncol"},{"key":"6630_CR15","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.celrep.2018.03.019","volume":"22","author":"T Fukumoto","year":"2018","unstructured":"Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R (2018a) Repurposing pan-HDAC inhibitors for ARID1A-mutated ovarian cancer. Cell Rep 22:3393\u20133400. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.019","journal-title":"Cell Rep"},{"key":"6630_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/23808993.2018.1503050","volume":"3","author":"T Fukumoto","year":"2018","unstructured":"Fukumoto T, Zhang R, Bitler BG (2018b) Epigenetic inhibitors for the precision treatment of ARID1A-mutant ovarian cancers: what are the next steps? Expert Rev Precis Med Drug Dev 3:233\u2013236. https:\/\/doi.org\/10.1080\/23808993.2018.1503050","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"6630_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41389-020-0224-1","volume":"9","author":"JM Gedminas","year":"2020","unstructured":"Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ (2020) Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis 9:41. https:\/\/doi.org\/10.1038\/s41389-020-0224-1","journal-title":"Oncogenesis"},{"key":"6630_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/15513818909022347","volume":"9","author":"WL Gerald","year":"1989","unstructured":"Gerald WL, Rosai J (1989) Case 2. Desmoplastic small cell tumor with divergent differentiation. Pediatr Pathol 9:177\u2013183. https:\/\/doi.org\/10.3109\/15513818909022347","journal-title":"Pediatr Pathol"},{"key":"6630_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-022-00334-8","volume":"27","author":"A Gschwind","year":"2022","unstructured":"Gschwind A, Marx C, Just MD, Severin P, Behring H, Marx-Bl\u00fcmel L, Becker S, Rothenburger L, F\u00f6rster M, Beck JF, Sonnemann J (2022) Tight association of autophagy and cell cycle in leukemia cells. Cell Mol Biol Lett 27:32. https:\/\/doi.org\/10.1186\/s11658-022-00334-8","journal-title":"Cell Mol Biol Lett"},{"key":"6630_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3892\/ijo.2011.1062","volume":"39","author":"J Hentschel","year":"2011","unstructured":"Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F (2011) BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML. Int J Oncol 39:585\u2013591. https:\/\/doi.org\/10.3892\/ijo.2011.1062","journal-title":"Int J Oncol"},{"key":"6630_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14737140.2023.2200171","volume":"23","author":"S Hovsepyan","year":"2023","unstructured":"Hovsepyan S, Giani C, Pasquali S, Di Giannatale A, Chiaravalli S, Colombo C, Orbach D, Bergamaschi L, Vennarini S, Gatz SA, Gasparini P, Berlanga P, Casanova M, Ferrari A (2023) Desmoplastic small round cell tumor: from state of the art to future clinical prospects. Expert Rev Anticancer Ther 23:471\u2013484. https:\/\/doi.org\/10.1080\/14737140.2023.2200171","journal-title":"Expert Rev Anticancer Ther"},{"key":"6630_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/acsptsci.5c00729","volume":"9","author":"KA Iyer","year":"2026","unstructured":"Iyer KA, Koynova-Tenchov R, Sasso JM, Thite T, Deng Y, Zhou QA (2026) The future of epigenetics: emerging technologies and clinical applications. ACS Pharmacol Transl Sci 9:506\u2013544. https:\/\/doi.org\/10.1021\/acsptsci.5c00729","journal-title":"ACS Pharmacol Transl Sci"},{"key":"6630_CR23","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41467-026-69488-9","volume":"17","author":"R Kaufman","year":"2026","unstructured":"Kaufman R, Flores G, Boguslawski EA, Kinn-Gurzo S, Chasse M, Beddows I, Adams M, Stout MC, Gaetano L, Lopez R, Veluvolu S, Fuller A, Kitchen-Goosen SM, Tolstyka ZP, Gedminas JM, Grohar PJ (2026) Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription. Nat Commun 17:2844. https:\/\/doi.org\/10.1038\/s41467-026-69488-9","journal-title":"Nat Commun"},{"key":"6630_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/0008-5472.CAN-23-3603","volume":"85","author":"A Kawai-Kawachi","year":"2025","unstructured":"Kawai-Kawachi A, Lenormand MM, Astier C, Herbel N, Cutrona MB, Ngo C, Garrido M, Eychenne T, Dorvault N, Bordelet L, Song F, Bouyakoub R, Loktev A, Romo-Morales A, Henon C, Colmet-Daage L, Vibert J, Drac M, Brough R, Schwob E, Martella O, Pinna G, Shipley JM, Mittnacht S, Zimmermann A, Gulati A, Mir O, Le Cesne A, Faron M, Honore C, Lord CJ, Chabanon RM, Postel-Vinay S (2025) Replication stress is an actionable genetic vulnerability in desmoplastic small round cell tumors. Cancer Res 85:154\u2013170. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3603","journal-title":"Cancer Res"},{"key":"6630_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102420118","author":"AM Klein","year":"2021","unstructured":"Klein AM, Biderman L, Tong D, Alaghebandan B, Plumber SA, Mueller HS, van Vlimmeren A, Katz C, Prives C (2021) MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2102420118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6630_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/2767-9764.CRC-25-0058","volume":"5","author":"SL Koppenhafer","year":"2025","unstructured":"Koppenhafer SL, Geary EL, Thomas MV, Croushore EE, Zimmerman JAO, Gedminas JM, Quelle DE, Dodd RD, Gordon DJ (2025) Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells. Cancer Res Commun 5:1034\u20131048. https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0058","journal-title":"Cancer Res Commun"},{"key":"6630_CR27","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1073\/pnas.0802091105","volume":"105","author":"JE Kravchenko","year":"2008","unstructured":"Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A 105:6302\u20136307. https:\/\/doi.org\/10.1073\/pnas.0802091105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6630_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nm1263","volume":"11","author":"G Kroemer","year":"2005","unstructured":"Kroemer G, Martin SJ (2005) Caspase-independent cell death. Nat Med 11:725\u2013730. https:\/\/doi.org\/10.1038\/nm1263","journal-title":"Nat Med"},{"key":"6630_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","volume":"13","author":"S Lain","year":"2008","unstructured":"Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, Woods J, Lane DP, Westwood NJ (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454\u2013463. https:\/\/doi.org\/10.1016\/j.ccr.2008.03.004","journal-title":"Cancer Cell"},{"key":"6630_CR30","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, Fang H, Hou X (2023) Targeting histone deacetylases for cancer therapy: trends and challenges. Acta Pharm Sin B 13:2425\u20132463. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.007","journal-title":"Acta Pharm Sin B"},{"key":"6630_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-1-0716-5150-6_6","volume-title":"Fluorescence in situ hybridization (FISH): application guide","author":"T Liehr","year":"2026","unstructured":"Liehr T (2026a) Commercial FISH probes. In: Liehr T (ed) Fluorescence in situ hybridization (FISH): application guide. Springer US, New York, NY, pp 55\u201367"},{"key":"6630_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-0716-5150-6_27","volume-title":"Fluorescence in situ hybridization (FISH): application guide","author":"T Liehr","year":"2026","unstructured":"Liehr T (2026b) Multiplex FISH and spectral karyotyping. In: Liehr T (ed) Fluorescence in situ hybridization (FISH): application guide. Springer US, New York, NY, pp 271\u2013277"},{"key":"6630_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s10637-017-0541-1","volume":"36","author":"C Marx","year":"2018","unstructured":"Marx C, Marx-Bl\u00fcmel L, Lindig N, Thierbach R, Hoelzer D, Becker S, Wittig S, Lehmann R, Slevogt H, Heinzel T, Wang ZQ, Beck JF, Sonnemann J (2018) The sirtuin 1\/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing\u2019s sarcoma cell line. Invest New Drugs 36:396\u2013406. https:\/\/doi.org\/10.1007\/s10637-017-0541-1","journal-title":"Invest New Drugs"},{"key":"6630_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13578-021-00571-y","volume":"11","author":"C Marx","year":"2021","unstructured":"Marx C, Schaarschmidt MU, Kirkpatrick J, Marx-Blumel L, Halilovic M, Westermann M, Hoelzer D, Meyer FB, Geng Y, Buder K, Schadwinkel HM, Siniuk K, Becker S, Thierbach R, Beck JF, Sonnemann J, Wang ZQ (2021) Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing\u2019s sarcoma cells. Cell Biosci 11:57. https:\/\/doi.org\/10.1186\/s13578-021-00571-y","journal-title":"Cell Biosci"},{"key":"6630_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4939-6527-4_3","volume":"1510","author":"L Marx-Bl\u00fcmel","year":"2017","unstructured":"Marx-Bl\u00fcmel L, Marx C, K\u00fchne M, Sonnemann J (2017) Assessment of HDACi-induced cytotoxicity. Methods Mol Biol 1510:23\u201345. https:\/\/doi.org\/10.1007\/978-1-4939-6527-4_3","journal-title":"Methods Mol Biol"},{"key":"6630_CR36","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1878-0261.13193","volume":"16","author":"C Megino-Luque","year":"2022","unstructured":"Megino-Luque C, Siso P, Mota-Martorell N, Navaridas R, de la Rosa I, Urdanibia I, Alberti-Valls M, Santacana M, Pinyol M, Bonifaci N, Macia A, Llobet-Navas D, Gatius S, Matias-Guiu X, Eritja N (2022) ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma. Mol Oncol 16:2235\u20132259. https:\/\/doi.org\/10.1002\/1878-0261.13193","journal-title":"Mol Oncol"},{"key":"6630_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030498","author":"CA Mello","year":"2021","unstructured":"Mello CA, Campos FAB, Santos TG, Silva MLG, Torrezan GT, Costa FD, Formiga MN, Nicolau U, Nascimento AG, Silva C, Curado MP, Nakagawa SA, Lopes A, Aguiar S Jr. (2021) Desmoplastic small round cell tumor: a review of main molecular abnormalities and emerging therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13030498","journal-title":"Cancers (Basel)"},{"key":"6630_CR38","first-page":"3769","volume":"30","author":"S Miwa","year":"2010","unstructured":"Miwa S, Kitamura S, Shirai T, Hayashi K, Nishida H, Takeuchi A, Nojima T, Tsuchiya H (2010) Desmoplastic small round cell tumour successfully treated with caffeine-assisted chemotherapy: a case report and review of the literature. Anticancer Res 30:3769\u20133774","journal-title":"Anticancer Res"},{"key":"6630_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/pharmrev.122.000612","volume":"75","author":"AM Mustafa","year":"2023","unstructured":"Mustafa AM, Kr\u00e4mer OH (2023) Pharmacological modulation of the crosstalk between aberrant Janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharmacol Rev 75:35\u201361. https:\/\/doi.org\/10.1124\/pharmrev.122.000612","journal-title":"Pharmacol Rev"},{"key":"6630_CR40","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/01.lab.0000028059.92642.03","volume":"82","author":"J Nishio","year":"2002","unstructured":"Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Yanai F, Nibu K, Mitsudome A, Kaneko Y, Kikuchi M (2002) Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1. Lab Invest 82:1175\u20131182. https:\/\/doi.org\/10.1097\/01.lab.0000028059.92642.03","journal-title":"Lab Invest"},{"key":"6630_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108672","volume":"260","author":"J Portugal","year":"2024","unstructured":"Portugal J (2024) Mithramycin and its analogs: molecular features and antitumor action. Pharmacol Ther 260:108672. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108672","journal-title":"Pharmacol Ther"},{"key":"6630_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cancergen.2011.07.008","volume":"204","author":"S Sankar","year":"2011","unstructured":"Sankar S, Lessnick SL (2011) Promiscuous partnerships in Ewing\u2019s sarcoma. Cancer Genet 204:351\u2013365. https:\/\/doi.org\/10.1016\/j.cancergen.2011.07.008","journal-title":"Cancer Genet"},{"key":"6630_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6:a018713. https:\/\/doi.org\/10.1101\/cshperspect.a018713","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6630_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2174\/138161211795222603","volume":"17","author":"H Shen","year":"2011","unstructured":"Shen H, Maki CG (2011) Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm des 17:560\u2013568. https:\/\/doi.org\/10.2174\/138161211795222603","journal-title":"Curr Pharm des"},{"key":"6630_CR45","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejca.2011.01.015","volume":"47","author":"J Sonnemann","year":"2011","unstructured":"Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, Beck JF (2011) Anticancer effects of the p53 activator nutlin-3 in Ewing\u2019s sarcoma cells. Eur J Cancer 47:1432\u20131441. https:\/\/doi.org\/10.1016\/j.ejca.2011.01.015","journal-title":"Eur J Cancer"},{"key":"6630_CR46","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/bjc.2013.742","volume":"110","author":"J Sonnemann","year":"2014","unstructured":"Sonnemann J, Marx C, Becker S, Wittig S, Palani CD, Kr\u00e4mer OH, Beck JF (2014) P53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br J Cancer 110:656\u2013667. https:\/\/doi.org\/10.1038\/bjc.2013.742","journal-title":"Br J Cancer"},{"key":"6630_CR47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ejca.2015.02.016","volume":"51","author":"J Sonnemann","year":"2015","unstructured":"Sonnemann J, Grauel D, Bl\u00fcmel L, Hentschel J, Marx C, Blumrich A, Focke K, Becker S, Wittig S, Schinkel S, Kr\u00e4mer OH, Beck JF (2015) RETRA exerts anticancer activity in Ewing\u2019s sarcoma cells independent of their TP53 status. Eur J Cancer 51:841\u2013851. https:\/\/doi.org\/10.1016\/j.ejca.2015.02.016","journal-title":"Eur J Cancer"},{"key":"6630_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2017.174","volume":"25","author":"KD Sullivan","year":"2018","unstructured":"Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM (2018) Mechanisms of transcriptional regulation by p53. Cell Death Differ 25:133\u2013143. https:\/\/doi.org\/10.1038\/cdd.2017.174","journal-title":"Cell Death Differ"},{"key":"6630_CR49","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1038\/onc.2008.311","volume":"27","author":"SW Tait","year":"2008","unstructured":"Tait SW, Green DR (2008) Caspase-independent cell death: leaving the set without the final cut. Oncogene 27:6452\u20136461. https:\/\/doi.org\/10.1038\/onc.2008.311","journal-title":"Oncogene"},{"key":"6630_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/B978-0-12-375709-8.00037-X","volume-title":"Handbook of epigenetics","author":"S Thomas","year":"2011","unstructured":"Thomas S, Miller A, Thurn KT, Munster P (2011) Chapter 37 - clinical applications of histone deacetylase inhibitors. In: Tollefsbol T (ed) Handbook of epigenetics. Academic Press, San Diego, pp 597\u2013615"},{"key":"6630_CR51","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, Oberlin O, Zaidi S, Lemmon G, Gupta P, Vadodaria B, Easton J, Gut M, Ding L, Mardis ER, Wilson RK, Shurtleff S, Laurence V, Michon J, Marec-Berard P, Gut I, Downing J, Dyer M, Zhang J, Delattre O, St. Jude Children\u2019s Research Hospital-Washington University Pediatric Cancer Genome P, International Cancer Genome C (2014) Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4:1342\u20131353. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0622","journal-title":"Cancer Discov"},{"key":"6630_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41388-025-03300-8","volume":"44","author":"F van Kampen","year":"2025","unstructured":"van Kampen F, Clark A, Soul J, Kanhere A, Glenn MA, Pettitt AR, Kalakonda N, Slupsky JR (2025) Deletion of 17p in cancers: guilt by (p53) association. Oncogene 44:637\u2013651. https:\/\/doi.org\/10.1038\/s41388-025-03300-8","journal-title":"Oncogene"},{"key":"6630_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/stke.3582006pe44","author":"P Vandenabeele","year":"2006","unstructured":"Vandenabeele P, Vanden Berghe T, Festjens N (2006) Caspase inhibitors promote alternative cell death pathways. Sci STKE. https:\/\/doi.org\/10.1126\/stke.3582006pe44","journal-title":"Sci STKE"},{"key":"6630_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41419-021-03902-6","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Thomas HR, Li Z, Yeo NCF, Scott HE, Dang N, Hossain MI, Andrabi SA, Parant JM (2021) Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis. Cell Death Dis 12:659. https:\/\/doi.org\/10.1038\/s41419-021-03902-6","journal-title":"Cell Death Dis"},{"key":"6630_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y (2023) Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther 8:92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1","journal-title":"Signal Transduct Target Ther"},{"key":"6630_CR56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-025-02549-5","volume":"11","author":"W Wang","year":"2026","unstructured":"Wang W, Liu X, Liu H, Abolhassani H, Yan H, Zhang H, Wang X (2026) p53: from understanding its structure to advances in therapeutic targeting. Signal Transduct Target Ther 11:121. https:\/\/doi.org\/10.1038\/s41392-025-02549-5","journal-title":"Signal Transduct Target Ther"},{"key":"6630_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-0716-5150-6_18","volume-title":"Fluorescence in situ hybridization (FISH): application guide","author":"A Weise","year":"2026","unstructured":"Weise A, Liehr T (2026) Pre- and postnatal diagnostics and research on peripheral blood, bone marrow chorion, amniocytes, and fibroblasts. In: Liehr T (ed) Fluorescence in situ hybridization (FISH): application guide. Springer US, New York, NY, pp 187\u2013197"},{"key":"6630_CR58","doi-asserted-by":"publisher","first-page":"eaao4170","DOI":"10.1126\/scisignal.aao4170","volume":"11","author":"ER Wolf","year":"2018","unstructured":"Wolf ER, McAtarsney CP, Bredhold KE, Kline AM, Mayo LD (2018) Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK. Sci Signal 11:eaao4170. https:\/\/doi.org\/10.1126\/scisignal.aao4170","journal-title":"Sci Signal"},{"key":"6630_CR59","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/sj.onc.1205262","volume":"21","author":"JC Wong","year":"2002","unstructured":"Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber DA (2002) Induction of the interleukin-2\/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene 21:2009\u20132019. https:\/\/doi.org\/10.1038\/sj.onc.1205262","journal-title":"Oncogene"},{"key":"6630_CR60","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","volume":"7","author":"QJ Wu","year":"2022","unstructured":"Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, Liu YS, Zheng G, Zhao JQ, Wei YF, Guo JY, Liu FH, Chang Q, Zhang YX, Liu CG, Zhao YH (2022) The sirtuin family in health and disease. Signal Transduct Target Ther 7:402. https:\/\/doi.org\/10.1038\/s41392-022-01257-8","journal-title":"Signal Transduct Target Ther"},{"key":"6630_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22327-5","volume":"12","author":"Y Xia","year":"2021","unstructured":"Xia Y, Liu Y, Yang C, Simeone DM, Sun TT, DeGraff DJ, Tang MS, Zhang Y, Wu XR (2021) Dominant role of CDKN2B\/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis. Nat Commun 12:2047. https:\/\/doi.org\/10.1038\/s41467-021-22327-5","journal-title":"Nat Commun"},{"key":"6630_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1084\/jem.182.2.367","volume":"182","author":"N Zamzami","year":"1995","unstructured":"Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G (1995) Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182:367\u2013377. https:\/\/doi.org\/10.1084\/jem.182.2.367","journal-title":"J Exp Med"},{"key":"6630_CR63","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/1535-7163.MCT-22-0119","volume":"21","author":"Y Zhan","year":"2022","unstructured":"Zhan Y, Zhou X, Peuget S, Singh M, Peyser BD, Fan Z, Selivanova G (2022) Decreased DNA damage and improved p53 specificity of RITA analogs. Mol Cancer Ther 21:1524\u20131534. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0119","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06630-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:04:23Z","timestamp":1791072263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06630-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6630"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06630-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"24 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"192"}}